Purpose: To clarify the efficacy of palliative radiotherapy for the relief of symptoms due to skin invasion in patients with breast cancer. Materials and methods: We conducted a multi-institutional prospective observational study of patients who received palliative radiotherapy for skin invasion due to a primary lesion or chest wall recurrence. Bleeding/discharge, offensive odor, pain and QOL scores were evaluated before and 1, 3 and 6 months after radiotherapy. Results: Twenty-one patients were assessed. Sixteen patients (76%) received 36 Gy in 12 fractions. The mean (±1 SD) score of bleeding/discharge was 1.90 ± 0.89 before radiotherapy, 1.50 ± 0.74 at 1 month, 0.47 ± 0.58 at 3 months, and 0.82 ± 1.04 at 6 months (P = 0.001). The mean score of offensive odor was 1.21 ± 1.38 before radiotherapy, 0.71 ± 0.92 at 1 month, 0.20 ± 0.41 at 3 months, and 0.27 ± 0.62 at 6 months (P = 0.008). The mean score of pain was 2.90 ± 1.22 before radiotherapy, 3.05 ± 1.36 at 1 month, 3.29 ± 1.10 at 3 months, and 3.31 ± 1.54 at 6 months (P = 0.431). The mean total score of QOL-ACD/QOL-ACD-B was 126.2 ± 24.5 before radiotherapy, 130.3 ± 26.3 at 1 month, 136.2 ± 26.6 at 3 months, and 126.6 ± 32.8 at 6 months (P = 0.178). Conclusion: Palliative radiotherapy for skin invasion in patients with breast cancer might be effective, especially for the relief of bleeding/discharge and offensive odor.
Introduction
Patients with advanced primary tumors of breast cancer or chest wall recurrence after mastectomy often develop symptoms associated with skin invasion, which significantly impairs the patients' quality of life (QOL) due to bleeding/discharge, offensive odor and pain (1) . Although palliative radiotherapy is recommended for patients with these symptoms (2) , its efficacy has been poorly defined (3, 4) . This study aimed to clarify the efficacy of palliative radiotherapy for the relief of symptoms due to skin invasion in patients with breast cancer.
Typically, a tangential opposed field of 4-6 MV X-rays with a tissue-equivalent bolus was used. The clinical target volume included the gross tumor volume that caused the symptoms. Dose fractionations were based on the physicians' preference, considering patients' performance status.
Materials and methods
With the approval of each institutional review board, we conducted a multi-institutional prospective observational study. The eligible patients were those who received palliative radiotherapy for skin invasion of the primary tumor or chest wall recurrence.
Endpoints
Bleeding/discharge, offensive odor, pain and QOL scores were evaluated before and 1, 3 and 6 months after radiotherapy. Using a 5-point scale, two observers (physician and nurse) independently assessed bleeding/discharge (0: none, 1: on contact, 2: intermittent, 3: continuous, 4: requires surgical intervention) and offensive odor (0: none, 1: subtle, 2: mild [noticeable around skin invasion], 3: moderate [noticeable around the patient], 4: severe [noticeable in the same room]). If scores differed between observers, the average scores were used. Patients rated pain on a 5-point scale ranging from 1 (severe) to 5 (no pain). Information on pain medication use (opioid agents, non-opioid agents or none) was also collected. A Japanese QOL questionnaire specifically designed for breast cancer patients (QOL questionnaire for cancer patients treated with anticancer drugs [QOL-ACD]/QOL-ACD-B) was used for QOL assessment (5, 6) . Adverse events were evaluated at 1, 3 and 6 months after radiotherapy based on the Common Terminology Criteria for Adverse Events version 3.0.
Statistical analysis
Statistical analysis was performed using SPSS version 22.0 (IBM, USA). Friedman's test was used to compare scores of bleeding/discharge, offensive odor, pain, and QOL-ACD/QOL-ACD-B before and 1, 3 and 6 months after radiotherapy. Endpoints with significant differences were then analyzed by the Wilcoxon signed-rank test to compare scores between two time points (before versus 1, 3 or 6 months after radiotherapy). The Wilcoxon signed-rank test was also used to compare pain medication use between each time point. Two-tailed P values less than 0.05 (Friedman's test) and 0.016 (Wilcoxon signed-rank test) were considered significant, taking multiplicity into account using Bonferroni correction.
Results
A total of 25 patients were recruited from three institutions from April 2014 to September 2016. Of these, 21 patients were assessed, excluding four patients who had died or had a poor performance status at 1 month after radiotherapy. Patient characteristics are shown in Table 1 .
Symptom relief and QOL improvement
Bleeding/discharge and offensive odor were significantly improved after radiotherapy (P = 0.001 and P = 0.008, respectively, by Friedman's test). Comparisons by the Wilcoxon signed-rank test showed significant improvements in bleeding/discharge at 3 months (P = 0.001) and 6 months (P = 0.009), and in offensive odor at 3 months (P = 0.005) (Figs. 1 and 2 ). No significant improvements were observed in pain (P = 0.431) (Fig. 3) , pain medication use (P = 0.087) ( Table 2 ), or total scores of QOL-ACD/QOL-ACD-B (P = 0.178) (Fig. 4) .
Adverse events
Grade 2 and 3 dermatitis was observed in one (5%) and two patients (10%), respectively. No other ≥Grade 2 adverse events were noted.
Discussion
To the best of our knowledge, this is the first prospective study to report on the efficacy of palliative radiotherapy for breast cancer with skin invasion. Bleeding/discharge and offensive odor significantly improved after palliative radiotherapy. Best responses were obtained at 3 months after radiotherapy for bleeding/discharge, offensive odor and QOL scores, suggesting that the re-progression of symptoms might have occurred at 6 months. As most patients received 36 Gy in 12 fractions, optimization of dose fractionation might be necessary to achieve higher rates and a longer duration of symptom relief.
No improvement in pain was observed in the present study. It was surprising because it is well-known that radiotherapy is effective for pain relief in the various palliative settings (7-10). In our study, few patients reported severe pain, and only 14% of patients took opioid agents before radiotherapy. The fact that pain was not the dominant symptom in our cohort might make it difficult to show the efficacy of radiotherapy on pain relief. In addition, no improvement in QOL scores was observed, suggesting that tumor progression outside the radiation field might have affected the QOL, irrespective of improvements in skin invasion symptoms.
We used 5-point scales that we defined by ourselves to assess bleeding/discharge and offensive odor. Our scales may be easy to apply. On the other hand, it is a limitation of our study that symptoms were evaluated using non-validated scales. The lack of validated scales, which hinders clinical research on palliative therapy for skin invasion, is an important issue that needs to be addressed in the future. Nonetheless, our findings provide new insights into palliative therapy for skin invasion, as strong evidence is not yet available.
In conclusion, palliative radiotherapy for skin invasion in patients with breast cancer might be effective, especially for the relief of bleeding/discharge and offensive odor.
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